Sutro Biopharma (STRO) Interest & Investment Income (2017 - 2026)

Sutro Biopharma has reported Interest & Investment Income for 9 years, with the latest figure at -$782000.0 in Q4 2025.

• Quarterly Interest & Investment Income rose 90.27% year-over-year to -$782000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.2 million (down 58.75% YoY) and the FY2025 annual result came in at -$3.9 million, down 120.68% from the prior year.
• Interest & Investment Income eased to -$782000.0 in Q4 2025 per STRO's latest filing, from -$737000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $22.2 million in Q3 2024 and troughed at -$8.0 million in Q4 2024.
• A 5-year average of $802500.0 and a median of $102500.0 in 2021 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2023: Interest & Investment Income surged 7706.25% in 2022, then plunged 2674.14% in 2023.
• Over 5 years, Interest & Investment Income stood at $96000.0 in 2021, then soared by 7706.25% to $7.5 million in 2022, then sank by 133.89% to -$2.5 million in 2023, then slumped by 216.54% to -$8.0 million in 2024, then surged by 90.27% to -$782000.0 in 2025.
• According to Business Quant data, Interest & Investment Income over the past three periods registered -$782000.0, -$737000.0, and $2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.